Results 31 to 40 of about 30,694,151 (287)
L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used.
M. Muthuraman +7 more
semanticscholar +1 more source
Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles +3 more
doaj +1 more source
3,4-dihydroxyphenyl-L-alanine (L-DOPA) is a preferred drug for Parkinson’s disease, with an increasing demand worldwide that mainly relies on costly and environmentally problematic chemical synthesis.
Jiping Zhao +4 more
doaj +1 more source
Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized by dopamine depletion in the striatum. One consistent pathophysiological hallmark of PD is an increase in spontaneous oscillatory activity in the basal ganglia ...
Youngbin Kwak +9 more
doaj +1 more source
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. [PDF]
L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study
Birger Scholz +11 more
doaj +1 more source
Introduction: Parkinson’s disease (PD), is a disorder debilitant characterized by the reduction of nigrostriatal dopaminergic neurons within the midbrain, specifically in the substantia nigra pars compacta, which results for the dopamine (DA) depletion ...
Lorenna Emília Sena Lopes (7860332) +3 more
core +1 more source
Detection of the drug Levodopa (3,4-dihydroxyphenylalanine, L-Dopa) is essential for the medical treatment of several neural disorders, including Parkinson’s disease.
R. Rubira +8 more
semanticscholar +1 more source
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. [PDF]
BackgroundRadiotracer imaging of the presynaptic nigrostriatal dopaminergic system is used to assess disease progression in Parkinson's disease (PD) and may provide a useful adjunct to clinical assessment during therapeutic trials of potential ...
Pierre-Olivier Fernagut +8 more
doaj +1 more source
Dopamine depletion in Parkinson's disease (PD) produces dendritic spine loss in striatal medium spiny neurons (MSNs) and increases their excitability. However, the synaptic changes that occur in MSNs in PD, in particular those induced by chronic L-3,4 ...
L. M. Suarez +4 more
semanticscholar +1 more source
Pramipexole in comparison to l-dopa: a neuropsychological study
Twenty right-handed patients affected by early/mild Parkinson's disease were evaluated in a randomised study using neuropsychological and clinical assessements during three treatment modalities: when in the off treatment condition, when on pramipexole ...
Peppe, A +9 more
core +1 more source

